1. Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group 
Scott A. Laurie, MD, FRCPC, Ashish Gupta, MBBS, MD, Quincy Chu, MD, FRCPC, Christopher W. Lee, MD, FRCPC, Wojciech Morzycki, MD, FRCPC, Ronald Feld, MD, FRCPC, Alison H. Foo, MSc, Jean Seely, MD, FRCPC, John R. Goffin, MD, FRCPC, Francis Laberge, MD, FRCPC, Nevin Murray, MD, FRCPC, Sanjay Rao, MD, FRCPC, Garth Nicholas, MD, MSc, FRCPC, Janessa Laskin, MD, FRCPC, Tony Reiman, MD, FRCPC, Delia Sauciuc, MD, FRCPC, Lesley Seymour, MD, PhD, FRCPC 
Journal of Thoracic Oncology 
Volume 6, Issue 11, Pages (November 2011)
DOI: /JTO.0b013e df5
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1.
Waterfall plot of responses. Note: one patient is not included, as developed disease progression (brain metastases) and did not have target lesions reimaged.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e df5)
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2. Overall survival.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e df5)
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3. Progression-free survival.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e df5)
Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions